CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Ohio ranked No. 1 for business by CNBC
July 10, 2026
Ohio is CNBC’s No. 1 Top State for Business in 2026. The University of Cincinnati helps fuel that success through co-op, innovation, talent development and close collaboration with the state.
UC students organize free health clinic happening July 11-12
July 10, 2026
The University of Cincinnati student chapter of Remote Area Medical is holding its annual free health clinic July 11-12. The clinic is open to adults and children, with no income requirements. Anyone in the area who needs medical, dental or vision care will have a chance to get it for free, with no insurance required.
Is speech-to-text AI really reliable?
July 10, 2026
UC researcher Nelly Elsayed’s study in the International Journal of Medical Informatics reveals key risks in clinical speech-to-text AI and shows why human review is essential.